PIM1 and neuroblastoma: In line with the inhibitory effects observed on N‐Myc protein levels following IBL‐302 treatment, PIM/PI3K targeting might have a stronger effect against MYCN‐amplified neuroblastoma as compared to non‐MYCN‐amplified tumors.